Click on the links below to preview selected pages from this course.
- Risk Markers
- Risk Factors
- Cardiovascular Risk Markers
- Atherosclerosis continued
- Patient Studies to Validate Risk Markers
- Framingham Score
- Which of the following is NOT a cardiovascular risk factor?
- Which of the following statements is true?
- Which of the following is NOT a factor used in the calculation of the Framingham Risk Score?
- Transport of Lipophilic Substances
- Lipoprotein Particles
- Apolipoproteins, continued
- What are apolipoproteins?
- Importance of Determining Size and Number of Lipoprotein Particles
- Measuring Apolipoproteins
- ApoB and ApoA1
- ApoB/ApoA1: The Test
- What can be said of a patient who has high ApoB and low ApoA1 concentrations?
- C-Reactive Protein
- Lipoprotein (a)
- Oxidized LDL
- Lipoprotein Particle Size and Number
- Size and Number
- Assessing Lipoprotein Particle Number and Size
- Nuclear Magnetic Resonance (NMR) Spectroscopy
- LDL Phenotype by Electrophoresis
- Electrophoresis Testing
- Measuring particle number instead of cholesterol content has which of the following features or limitations?
- Homocysteine: Past and Present.
- Interpreting Risk Marker Results
- A Caveat...
- Which biomarkers of cardiac disease risk are inflammatory markers?
Level of instruction: Intermediate
Intended Audience: Clinical laboratory technologists and technicians, and other health care personnel who have an interest in this subject matter. This course is also appropriate for clinical laboratory science students and pathology residents.
Author Information: Kevin F. Foley, PhD, DABCC, MT, SC is the Northwest chemistry, toxicology, immunology and POC director for Kaiser Permanente. He also teaches pharmacology, clinical chemistry, immunology and medicinal chemistry at Oregon Health Sciences University. Dr. Foley earned his PhD in clinical pharmacology and toxicology at East Carolina School of Medicine in North Carolina. His research areas include cardiovascular risk and inflammation markers as well as the neuropharmacology of amphetamine-like compounds. He is a frequent contributor to several clinical laboratory publications and is active in the American Association of Clinical Chemistry.
Reviewer information: John Contois, PhD, DABCC, FACB is the Manager of Research and Development for Maine Standards Company. He holds a MS and PhD in Nutritional Sciences from the University of Connecticut and an MBA from the University of North Carolina and is certified as a Diplomate with the American Board of Clinical Chemistry and a Fellow with the National Academy of Clinical Biochemistry. Dr. Contois has a patent pending on a method for measuring the number of atherogenic low density lipoprotein particles in blood.